Lifesci Capital Forecasts Disc Medicine Q2 Earnings

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Equities research analysts at Lifesci Capital issued their Q2 2025 EPS estimates for shares of Disc Medicine in a report released on Monday, June 16th. Lifesci Capital analyst R. Katkhuda expects that the company will post earnings per share of ($1.05) for the quarter. The consensus estimate for Disc Medicine's current full-year earnings is ($4.07) per share. Lifesci Capital also issued estimates for Disc Medicine's Q3 2025 earnings at ($1.07) EPS.

A number of other research analysts have also recently issued reports on the company. Cantor Fitzgerald boosted their target price on Disc Medicine from $99.00 to $132.00 and gave the company an "overweight" rating in a research note on Tuesday, March 18th. Raymond James Financial began coverage on Disc Medicine in a research report on Wednesday, June 11th. They issued a "strong-buy" rating and a $89.00 price objective for the company. BMO Capital Markets raised their target price on shares of Disc Medicine from $112.00 to $120.00 and gave the stock an "outperform" rating in a report on Monday, May 12th. Morgan Stanley reaffirmed an "overweight" rating and issued a $85.00 price target on shares of Disc Medicine in a research note on Friday, March 7th. Finally, HC Wainwright reissued a "buy" rating and set a $118.00 price objective on shares of Disc Medicine in a research report on Tuesday. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $96.70.

Disc Medicine Trading Up 3.0%

Shares of IRON traded up $1.52 during trading hours on Tuesday, reaching $51.61. The stock had a trading volume of 413,971 shares, compared to its average volume of 346,039. The company has a market cap of $1.79 billion, a P/E ratio of -13.17 and a beta of 0.73. Disc Medicine has a 52 week low of $30.82 and a 52 week high of $68.73. The company has a quick ratio of 37.65, a current ratio of 37.65 and a debt-to-equity ratio of 0.04. The firm has a 50-day moving average of $46.96 and a 200 day moving average of $52.97.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.03).

Insider Transactions at Disc Medicine

In related news, insider William Jacob Savage sold 2,996 shares of Disc Medicine stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $50.00, for a total value of $149,800.00. Following the sale, the insider now owns 56,725 shares of the company's stock, valued at approximately $2,836,250. The trade was a 5.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Jean M. Franchi sold 2,000 shares of the company's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $52.26, for a total value of $104,520.00. Following the sale, the chief financial officer now owns 67,530 shares in the company, valued at $3,529,117.80. The trade was a 2.88% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 19,511 shares of company stock valued at $1,004,277 over the last 90 days. 4.24% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers boosted its holdings in shares of Disc Medicine by 10.7% in the 1st quarter. Rhumbline Advisers now owns 32,144 shares of the company's stock valued at $1,596,000 after buying an additional 3,108 shares during the last quarter. Strs Ohio acquired a new position in Disc Medicine during the first quarter worth $347,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Disc Medicine by 3.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 96,557 shares of the company's stock worth $4,793,000 after acquiring an additional 3,454 shares in the last quarter. Woodline Partners LP raised its position in Disc Medicine by 26.6% during the first quarter. Woodline Partners LP now owns 502,230 shares of the company's stock worth $24,931,000 after acquiring an additional 105,630 shares in the last quarter. Finally, Zimmer Partners LP lifted its stake in Disc Medicine by 29.6% in the first quarter. Zimmer Partners LP now owns 42,900 shares of the company's stock valued at $2,130,000 after acquiring an additional 9,800 shares during the last quarter. Institutional investors and hedge funds own 83.70% of the company's stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.